Conditions: Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 30
Healthy volunteers: yes

Brief summary:
This is a study that involves multiple doses of study drug (60 mg of LY2409021, 15 mg of LY2409021 or placebo) taken as capsules by mouth on a daily basis for 28 days. This study will image the liver using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in healthy participants and in participants with type 2 diabetes mellitus, when they take LY2409021 to see if liver changes happen at the same time as changes in blood tests. This study is approximately 11 weeks long, not including screening. A screening appointment is required within 28 days prior to the start of the study.

Detailed description:

Arms:
arm 1: Part A and B - Up to 4 capsules of placebo administered orally once a day for 28 days. arm 2: Part B - 1 capsule of 15 mg LY2409021 orally once a day for 28 days. (Arm added in September, 2012, per protocol amendment.) arm 3: Part A - 4 capsules of 15 mg LY2409021 administered orally once a day for 28 days.

Interventions: intervention 1: Placebo intervention 2: LY2409021
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally

Protocol document: